Dr. Scott Gottlieb, a partner at one of the world's largest venture capital funds and a former deputy commissioner at the U.S. Food and Drug Administration, is being considered by President-elect Donald Trump to run the agency, according to sources close to the transition team.
Gottlieb is being considered alongside Jim O'Neill, a self-declared libertarian and colleague of Peter Thiel, the co-founder of Mithril Capital Management who was an early Trump supporter and is now advising his transition team. Bloomberg News first reported that Trump was looking at O’Neill (read “Why Donald Trump's Putative FDA Pick Should Scare Pharma & Patients”; http://sco.lt/62EHSL).
Gottlieb would be a more traditional choice than O’Neill and fits the profile of what Trump’s administration seems to be looking for.
Gottlieb's ties to the pharmaceutical industry run deep. He sits on the boards of multiple companies and advises others, including the British pharmaceutical giant GlaxoSmithKline Plc.
Between 2003 and 2004 Gottlieb was a senior adviser to the FDA commissioner and then the agency’s director of medical policy development. In 2004 he also acted as senior adviser to the Centers for Medicare and Medicaid Services.
From 2005-2007 he was the FDA's deputy commissioner for medical and scientific affairs.